Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,669 recruiting studies in this area right now.
By phase
- Not applicable9,830
- Phase 24,462
- Phase 12,741
- Phase 1/Phase 21,687
- Phase 31,405
- Phase 2/Phase 3281
- Phase 4263
Top conditions
- Breast Cancer1,229
- Cancer659
- Prostate Cancer657
- Colorectal Cancer496
- Lung Cancer428
- Ovarian Cancer338
- Multiple Myeloma329
- Gastric Cancer300
- Pancreatic Cancer296
- Acute Myeloid Leukemia293
- Hepatocellular Carcinoma284
- Solid Tumor258
- Advanced Solid Tumor256
- Cervical Cancer232
- Head and Neck Cancer229
- Endometrial Cancer205
- Advanced Solid Tumors195
- Esophageal Cancer193
Leading sponsors
- M.D. Anderson Cancer Center451
- Fudan University311
- Memorial Sloan Kettering Cancer Center289
- Sun Yat-sen University289
- National Cancer Institute (NCI)288
- Mayo Clinic238
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center144
- AstraZeneca132
- University Health Network, Toronto125
Where studies are running
- California1,425
- Texas641
- Arizona513
- Florida446
- Alabama420
- New York412
- Massachusetts340
- Maryland328
- New Jersey268
- Pennsylvania241
Recruiting studies20,669 total
- NCT05401097RecruitingPhase 2
Venetoclax plus IDH-targeted pills for AML patients who can’t get intensive chemo
This Phase 2 trial tests different ways of using medicines that target IDH mutations (IDH-targeted treatment) plus venetoclax in people newly diagnosed with IDH-mutated AML. It’s designed for patients who cannot safely receive intensive induction chemotherapy, to see which approach works best and is tolerable.
Aurora, ColoradoAges 18 years+ - NCT05401318Recruiting
Personalized treatment planning for colorectal cancer surgery
This study focuses on tailoring (customizing) treatment plans for people with colorectal cancer who are scheduled for curative surgery. It may help doctors choose the most appropriate treatment approach after surgery using standard follow-up information.
Lørenskog, AkershusAges 18 years+ - NCT05403177Recruiting
Share your cancer data and samples for Ontario research
This study collects and combines medical records, genetic (genomic) data, and tumor/blood samples from people with cancer. It helps researchers build and improve a large “gold standard” cancer dataset that can support future studies and better understanding of cancer.
Kingston, OntarioAges 18 years+ - NCT05403554RecruitingPhase 1
Testing a new mesothelin-targeting drug for certain solid cancers
This Phase 1 study tests NI-1801, a drug designed to attach to a target on cancer cells (mesothelin). It may be given alone or with pembrolizumab to help shrink tumors in advanced cancers that have enough mesothelin on their cells.
ParisAges 18 years+ - NCT05406856Recruiting
Adaptive proton therapy for cervical cancer with chemo
This trial tests whether an “adaptive” type of radiation planning using proton therapy and MRI-guided brachytherapy can improve treatment for people with cervical cancer. It aims to deliver curative treatment more precisely while still combining it with chemotherapy (cisplatin) when appropriate.
LeidenAges 18 years+ - NCT05404347Recruiting
Testing treatment response in gallbladder cancer patients
This trial studies how gallbladder cancer responds to treatment. It is for people newly diagnosed who have confirmed cancer in biopsy results.
Varanasi, Uttar PradeshAges 18–99 - NCT05404321Recruiting
Collecting tumor samples to study triple-negative breast cancer treatments
This study collects tumor tissue from people with early-stage triple-negative breast cancer before they start neoadjuvant chemotherapy. The goal is to help researchers test new therapies and look for markers that may predict who benefits.
CaenAges 18 years+ - NCT05404230Recruiting
Preventing nerve damage from oxaliplatin in the hands and feet
This study looks at ways to prevent numbness or nerve pain in the hands and feet that can happen from oxaliplatin treatment. It includes people with colon or rectal cancer who will be getting standard chemotherapy with capecitabine plus oxaliplatin.
AalborgAges 18 years+ - NCT05404906RecruitingPhase 2/Phase 3
Azacytidine plus venetoclax to prevent AML coming back
This trial studies azacytidine (AZA) plus venetoclax as maintenance treatment to help keep acute myeloid leukemia (AML) in first remission. It may help delay or prevent AML from returning in younger adults who cannot get a stem cell transplant right away.
Suzhou, JiangsuAges 18–64 - NCT05406167Recruiting
Tracking quality of life during radiotherapy with a new system
This study collects information about how you feel and how treatment is delivered while you receive radiotherapy using the RefleXion Medical radiotherapy system. It may help doctors improve care and better understand what affects quality of life during treatment.
Duarte, CaliforniaAges Any age - NCT05405270Recruiting
Testing how well imiquimod works for abnormal cervix cell changes
This study looks for ways to predict who will respond to imiquimod cream for precancerous cervical cell changes (CIN2 or CIN3). Results may help doctors choose the best treatment approach and better plan follow-up.
BredaAges 18 years+ - NCT05405413RecruitingPhase 2
Personalized cancer treatment plan guided by tumor gene results
This Phase 2 study uses a team review of your tumor’s gene test results to help match you with treatments you may benefit from. It’s designed for people whose tumor has specific gene changes that suggest sensitivity to available medicines or may involve inherited (germline) risk.
Lebanon, New HampshireAges 18 years+ - NCT05405387RecruitingPhase 2
Budesonide to prevent serious diarrhea after stem cell transplant
This Phase 2 study tests whether budesonide can lower the chance of moderate-to-severe diarrhea in people with multiple myeloma who are getting an autologous stem cell transplant. It may help your comfort and reduce complications during the transplant recovery period.
Salt Lake City, UtahAges 18 years+ - NCT05405673Recruiting
Test stool or tissue genes to find advanced colon growth
This study checks how well a set of bacterial gene markers (a DNA-like test) can help identify advanced “precancer-like” or higher-risk growths in the colon. It may help doctors better target who needs closer follow-up during colonoscopy.
Hong KongAges 18 years+ - NCT05406232Recruiting
Radiation study to track immune changes in breast cancer
This study gives a short course of radiation to the breast or chest wall and measures how your immune system responds. It may help doctors better understand which immune changes happen after radiation and how this could improve palliative (symptom-relieving) care.
Houston, TexasAges 18 years+ - NCT05407519RecruitingPhase 2
Tislelizumab and sitravatinib after liver cancer surgery to prevent relapse
This trial studies whether combining two medicines (tislelizumab and sitravatinib) given after curative liver cancer surgery can help prevent the cancer from coming back. It is for people with liver cancer at high risk of recurrence, who have fully recovered from surgery and have no spread beyond the liver.
Hefei, AnhuiAges 18–70 - NCT05408221RecruitingPhase 2/Phase 3
Liver cancer trial testing Rulonilimab plus Lenvatinib
This Phase 2/3 study tests whether combining rulonilimab with lenvatinib can control unresectable advanced liver cancer (HCC) that cannot be removed by surgery or treated locally. You may be considered if you have not had prior whole-body (systemic) cancer treatments and your organs and blood counts are strong enough.
Beijing, Beijing MunicipalityAges 18–75 - NCT05408845RecruitingPhase 2
Study drug vs standard care for HER2 salivary gland cancer
This Phase 2 trial tests how well ado-trastuzumab emtansine (and compares to two standard treatment options) works for salivary gland cancers that are HER2-positive or HER2-low. It aims to see whether the study drug can control cancer better and with acceptable side effects.
Birmingham, AlabamaAges 18 years+ - NCT05408897Recruiting
Blood test to predict risk after surgery for high-risk GIST
This study uses a “liquid biopsy” blood test to look for leftover cancer signals after surgery. It aims to predict how well treatment will work and how likely the cancer is to come back in people with high-risk GIST.
Beijing, Beijing MunicipalityAges Any age - NCT05409482Recruiting
Areal-world test of camrelizumab plus apatinib for liver cancer
This study looks at how well a combination of camrelizumab and apatinib works for people with unresectable hepatocellular carcinoma (liver cancer you can’t remove with surgery). It is designed to see results in real-life care for patients who have limited options after standard treatment.
Fuzhou, FujianAges 18–75 - NCT05410717RecruitingPhase 1
CAR-NK cell therapy for certain solid tumors
This early-phase trial tests a lab-made immune cell treatment for advanced solid tumors that show specific targets (including Claudin 6, GPC3, Mesothelin, or AXL). It may help the immune system better recognize and kill tumor cells, but eligibility depends on test results and your overall health.
Guangzhou, GuangdongAges 18–75 - NCT05410977Recruiting
Testing blood and stool for colon cancer in Lynch syndrome
This study collects blood and stool samples to see how well they can detect colorectal cancer or advanced growths in people with Lynch syndrome (an inherited colon cancer risk) or suspected Lynch syndrome. It may help find cancer or precancer earlier, which can improve next-step decisions.
Scottsdale, ArizonaAges 18 years+ - NCT05411666Recruiting
Optimizing care for a fully implanted chemotherapy vein port
This study focuses on the best way to maintain a fully implanted vein catheter (a port used for chemotherapy). It may help reduce complications and improve how safely your catheter is maintained after chemotherapy ends.
BragaAges 18 years+ - NCT05411718RecruitingPhase 2
Aspirin or naproxen to prevent cancer in Lynch syndrome
This trial tests whether daily aspirin or naproxen can “intercept” (stop) cancer from starting or coming back in people with Lynch syndrome who are currently cancer-free. Participants are randomly assigned to one of the two drugs, and neither the participant nor the team knows which one you’re taking.
Houston, TexasAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,669 recruiting oncology studies from the U.S. registry right now, out of 31,797 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.